Currently, thefour foundational classes of HF medications used in adults-angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers(ARBs)/ARNIs, β-blockers (BBs), mineralocorticoid receptor antagonists(MRAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors—are increasingly incorporated into pediatric HFmanagement. This evidence concerns the gene NR3C2 and hydrops fetalis.